

### von Willebrand Factor Concentrates

Manufacturer	Product	Type	Indication
CSL Behring	Humate-P®	Plasma-derived FVIII/VWF Complex. Average ratio of VWF:RCo to FVIII is 2.4:1.	Adults and children with severe VWD (type 3), and patients with mild to moderate VWD where the response to desmopressin (DDAVP) is known or suspected to be inadequate. Not indicated for prophylaxis.
Grifols	Alphanate®	Plasma-derived FVIII/VWF Complex. Average ratio of VWF:RCo to FVIII is 1.3:1 (varies by lot).	Control and prevention of bleeding in patients with hemophilia A, and patients with VWD where desmopressin (DDAVP) is either ineffective or contraindicated. Not indicated for patients with type 3 VWD undergoing major surgery.
Octapharma	wilate®	Plasma-derived FVIII/VWF Complex. Ratio of VWF:RCo to FVIII is 1:1.	Adults and children with type 3 VWD, and patients with mild to moderate VWD where the response to desmopressin (DDAVP) is known or suspected to be inadequate. Not indicated for prophylaxis.
Shire	Vonvendi	Recombinant VWF (contains no FVIII).	On-demand treatment and control of bleeding episodes in adults with VWD. Administer first dose with a recombinant FVIII-only product if FVIII baseline levels are below 40% or are unknown (this applies to all type 3 patients).

VWD: von Willebrand disease. VWF: von Willebrand factor. RCo: von Willebrand ristocetin cofactor (VWF:RCo) assay. aPCC: activated prothrombin complex concentrate.

© 2018 LA Kelley Communications, Inc. All rights reserved.